P-315: Temporal plasma profiles of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in patients with left ventricular hypertrophy

• Published in: American journal of hypertension 2005-05, Vol.18 (S4), p.120A-120A
• Main Authors: Clark, Leslie L., Bonnema, David D., Ahmed, S.H., Hardin, Amy E., Finklea, Laura, McClure, Catherine D., Lackland, Daniel T., Zile, Michael R., Spinale, Francis G.
• Format: Article
• Language: English
• Subjects: Left Ventricular Hypertrophy; Matrix Metalloproteinase
• ISSN: 0895-7061; 1941-7225; 1879-1905
• DOI: 10.1016/j.amjhyper.2005.03.333

The structure of the myocardial matrix is dependent on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). LV remodeling in left ventricular hypertrophy (LVH) involves changes in the matrix which is mediated by the MMP/TIMP system. The central hypothesis of this study was that a specific MMP/TIMP plasma profile occurs in LVH. Methods: Left ventricular (LV) echocardiography was performed in 58 LVH patients (Age: 61 ± 2 years; systolic blood pressure: 139±3 mmHg) and 42 controls with no evidence of cardiovascular disease (Age: 52 ± 2; systolic blood pressure: 124±mmHg). Plasma was collected and MMP-2, -9, -13 and TIMP-1 and -2 levels were quantified by high sensitivity enzyme linked immunoassay (ELISA). LVH patients were serially measured at baseline, 6 and 12 months while control values one baseline timepoint. Despite blood pressure control to JNC VII guideline, LV mass remained elevated in LVH patients through the 12 month follow-up period. Additionally, LVH patients had elevated TIMP-1 and TIMP-2 levels and were less likely to have detectable levels of MMP-13. Conclusions: After 12 months of follow-up, LVH patients demonstrated persistent hypertrophy and a specific temporal profile of MMPs and TIMP. Notably, the greater than 50% reduction in detectable MMP-13 (detectable in 40% of controls vs. 11% of LVH at 12 months, p